Lundbeck Partners with Danish AI Centre to Boost Drug Discovery

H. Lundbeck A/S has announced a collaboration with the Danish Centre for AI Innovation to leverage the Gefion AI supercomputer for drug discovery, announced in a press release. This partnership aims to accelerate the development of treatments for neurological and psychiatric disorders by utilizing Gefion's advanced AI capabilities.

Gefion, Denmark's flagship AI supercomputer, will provide Lundbeck with AI-driven insights into molecule discovery and drug optimization. This initiative is expected to enhance the discovery of next-generation treatments for brain disorders, which affect a significant portion of the global population.

Lundbeck's Senior Vice President & Head of Research, Tarek Samad, highlighted the potential of AI-driven innovation in advancing their Focused Innovator strategy. The collaboration with DCAI marks a significant step in transforming brain disease research through AI, providing researchers with access to state-of-the-art computational resources.

Nadia Carlsten, CEO of the Danish Centre for AI Innovation, expressed enthusiasm about working with Lundbeck, noting the potential of Gefion to accelerate the development of impactful neurological therapies. This partnership underscores the transformative role of AI supercomputing in addressing urgent healthcare challenges.